Understanding how mutant p53/YAP proteins affect treatment resistance in head and neck cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with head and neck tumors to analyze the mutational, transcriptional, and proteomic profiles of their tissue samples. It aims to characterize the molecular networks influenced by the mutated p53 protein, which plays a significant role in local recurrence of head and neck squamous cell carcinoma (HNSCC). By comparing primary tumors to recurrent tissues, the study seeks to identify key factors contributing to therapy resistance and explore potential new treatment strategies. The research includes both retrospective and prospective cohorts, utilizing advanced techniques such as single-cell RNA sequencing and organoid cultures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age over 18
* Patients with squamous cell tumors of the oral cavity, pharynx or larynx
* Surgical patients with primary HNSCC tumors, who have not had previous tumors in other sites or adjuvant treatments prior to surgery.
* Availability of adequate material (tissue) for the planned analyses
* Availability of follow-up data for at least one year (retrospective part)
* Written informed consent (prospective part and/or, for the retrospective part, traceable patients and/or patients in follow-up and/or if necessary for the legal nature/institutional purposes of the participating centers).

Exclusion Criteria:

* Presence of distant metastases at the time of diagnosis
* Previous head and neck cancer
* Second cancer undergoing treatment or follow-up for less than 5 years

Where it's running

• IRCCS National Cancer institute
  Roma, Rome, Italy Recruiting

Study contacts

• Principal investigator: Giovanni Blandino, Doctor — IRCCS National Cancer Institute
• Study coordinator: Giovanni Blandino, Doctor
• Email: giovanni.balndino@ifo.it
• Phone: +39 06 52662911

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SI-B036 in head and neck and other solid tumors: a first-in-human study

  This early-phase study tests SI-B036 in adults with locally advanced or metastatic head and neck cancers and other solid tumors to see if it is safe and tolerable, and to get initial clues about its activity.

  Recruiting at 2 sites Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Changsha, Hunan and 1 other locations · NCT07763639

• LRRC15-targeted PET imaging for more precise diagnosis and staging of pancreatic, breast, lung, sarcoma and head-and-neck cancers

  This project tests whether an LRRC15-targeted PET scan can better detect and stage LRRC15-expressing cancers and measures how the tracer behaves in healthy adults.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07552467

• Understanding metal elements in radiation-induced mouth sores

  This study is trying to see if certain metal elements in the body can help predict how severe mouth sores will be for patients getting radiation treatment for head and neck cancer.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT06968520

• Using breath analysis to predict mouth sores from radiotherapy in head and neck cancer patients

  This study is testing whether analyzing breath samples can help predict mouth sores in head and neck cancer patients receiving radiotherapy.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT06767488

• Targeted alpha therapy [212Pb]VMT-Alpha-NET for SSTR-positive metastatic or inoperable GI neuroendocrine, pheochromocytoma/paraganglioma, small cell lung, kidney, and head & neck cancers

  This trial will try an experimental targeted alpha-particle drug called [212Pb]VMT-Alpha-NET in adults whose metastatic or inoperable tumors show somatostatin receptor (SSTR) expression.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06479811

• Combining tislelizumab with chemotherapy for advanced head and neck tumors

  This study is testing if combining a new immune treatment called tislelizumab with chemotherapy can help people with advanced head and neck tumors feel better and improve their treatment outcomes.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT05758389

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.